# DESCRIPTION

## FIELD OF THE INVENTION

- relate to neurology and neurobiology

## BACKGROUND

- introduce CADASIL
- describe CADASIL symptoms
- discuss CADASIL prevalence
- explain NOTCH3 gene mutation
- describe NOTCH3 gene mutation effects
- discuss lack of CADASIL treatment
- describe VSMCs and pericytes
- explain Notch3ECD mutations
- describe CADASIL pathology
- discuss R90C mutation
- describe transgenic mouse model
- discuss CADASIL-related vascular pathology
- describe cerebrovascular dysfunction
- discuss Notch3ECD/GOM aggregation
- describe cognitive decline

## SUMMARY

- introduce method for improving neurological function
- describe VEGF administration
- discuss VEGF isoforms
- describe pharmaceutically acceptable forms
- introduce method for improving neurological function with VEGF
- describe administration of VEGF and G-CSF
- describe administration of VEGF and SCF
- introduce method for improving neurological function with G-CSF and SCF
- describe administration of G-CSF and SCF
- describe administration of SCF alone or with G-CSF

## DETAILED DESCRIPTION

- treat CADASIL in subjects
- compositions and methods for preventing, treating, or ameliorating CADASIL
- administering VEGF to a brain of a subject
- increasing the amount of VEGF in a subject
- VEGF, or functional isoforms thereof, include one or more of VEGFa, VEGFb, VEDFc, or combinations
- VEGF, or functional isoforms thereof, have a specific amino acid sequence
- administering VEGF, or functional isoforms thereof, includes administering one or more pharmaceutically acceptable agents
- method of improving neurological function in a mammal suffering from CADASIL
- administering an effective amount of a composition including a granulocyte colony-stimulating factor (G-CSF) polypeptide
- advantageously target decreased and/or deficient VEGF for developing new treatments
- provide improvement in neurological function characterized by slowing the progress of CADASIL
- pharmaceutical composition in an amount to form a therapeutically effective amount of active ingredient

### Definitions

- define singular forms
- define "about," "approximately," and the like
- define "drug," "drug substance," "active pharmaceutical ingredient"
- define "cDNA"
- define "degree of identity"
- define "excipient" or "adjuvant"
- define "drug product," "pharmaceutical dosage form," "dosage form"
- define "pharmaceutically acceptable" substances
- define "pharmaceutical composition"
- define "pharmaceutically acceptable salt"
- define "peptide," "polypeptide," and "protein"
- define "pharmaceutically acceptable vehicle"
- define "prevent", "preventing" and "prevention" of CADASIL disease
- define "recombinant"
- define "subject"
- define "substantially purified"
- define "therapeutically effective amount"
- define "treatment"
- describe general methods in molecular and cellular biochemistry
- describe the scope of the invention
- describe the terminology used
- describe the ranges of values
- describe the publications mentioned

### DESCRIPTION OF CERTAIN EMBODIMENTS

- introduce CADASIL treatment
- describe VEGF administration
- detail VEGF isoforms
- specify amino acid sequences
- describe G-CSF and SCF polypeptides
- outline pharmaceutical composition
- describe pharmaceutically acceptable salts
- detail recombinant excipients
- introduce method 100
- describe G-CSF and SCF administration
- outline neurological function improvement
- detail cognitive function improvement
- describe angiogenesis and vascular cell proliferation
- outline neurogenesis and synaptogenesis
- introduce method 200
- describe SCF polypeptide administration
- outline sensorimotor skills improvement
- detail VEGF and VEGF-regulated angiogenesis
- introduce method 300
- describe G-CSF polypeptide administration
- outline sensorimotor skills improvement
- describe pharmaceutical composition
- detail pharmaceutically acceptable carriers
- outline VEGF function bolstering
- describe active pharmaceutical ingredients
- detail VEGF isoforms and salts
- outline pharmaceutical composition preparation
- describe excipients and vehicles
- detail auxiliary substances
- outline pharmaceutical composition administration
- describe injectable compositions
- outline suspension and solution preparation
- describe peptide or salt concentration
- outline administration routes
- describe cDNA and nucleic acid sequences
- outline VEGF protein expression
- describe mammalian expression systems
- outline nucleic acid vector administration
- describe SCF and G-SCF administration
- outline CADASIL treatment methods

### EXAMPLES

- introduce example section
- describe CADASIL disease
- motivate VEGF as therapeutic target
- introduce SCF and G-CSF
- describe synergistic effects of SCF and G-CSF
- summarize previous studies on SCF and G-CSF
- describe experimental design
- introduce TgNotch3R90C mice model
- describe treatment groups
- describe bevacizumab (AVASTIN) treatment
- summarize major findings
- describe VEGF protein levels in TgNotch3R90C mice
- describe SCF+G-CSF treatment effects on VEGF
- describe water maze test results
- describe immunohistochemistry and histochemistry analyses
- describe blood vessel density in TgNotch3R90C mice
- describe SCF+G-CSF treatment effects on blood vessels
- describe bevacizumab (AVASTIN) pretreatment effects
- describe primary culture of endothelial cells (ECs) isolated from TgNotch3R90C mice
- describe EC proliferation and tube formation
- describe SCF+G-CSF treatment effects on ECs
- describe bevacizumab (AVASTIN) pretreatment effects on ECs
- describe neurostructural regeneration, synaptogenesis, and neurogenesis
- describe correlation analysis between blood vessel density and neurogenesis
- summarize findings on VEGF and CADASIL
- describe implications for CADASIL treatment
- conclude importance of VEGF in CADASIL
- describe Example II
- measure VEGF-A levels in Tg-VSMCs and Tg-pericytes
- depict immunohistochemistry data of VEGF expression
- analyze VEGF-A and phosphorylated VEGFR2 levels
- demonstrate role of VEGF in supporting mural cell survival
- analyze cell death rate in VSMCs
- perform RNA sequencing approach
- identify upstream regulators and regulatory networks
- analyze ERK and NF-kB signaling activations
- demonstrate restoration of affected cell signaling activation
- show decreased VEGF production and signaling activation
- confirm decreased blood vessel density in CADASIL patients
- demonstrate VEGF's role in pathogenesis and development of CADASIL
- block SCF+G-CSF-enhanced angiogenesis with bevacizumab
- analyze effects of SCF+G-CSF on VEGF production
- describe Prophetic Example I
- administer VEGF to treat CADASIL disease
- describe Prophetic Example II
- administer SCF and G-CSF to treat CADASIL disease
- increase total amount of VEGF in patient
- incorporate references by citation

